Revenue from operations jumped 17.7% to Rs 1,486.15 crore in the June quarter from Rs 1,262.14 crore recorded in Q1 FY23.

The company reported a profit before tax of Rs 129.76 crore in Q1 FY24 as compared to a pre tax loss of Rs 67.38 crore posted in the same period a year ago.

EBIDTA zoomed to Rs 210 crore in Q1 FY24 from Rs 9 crore reported in Q1 FY23. EBIDTA margin soared to 14% in Q1 FY24 as against 1% in Q1 FY23.

On the segmental front, API revenue was Rs 305 crore (up 31% YoY). In the Formulations business, India revenue was Rs 524 crore (up 9% YoY), US revenue was Rs 390 crore (up 6% YoY) and Ex-US revenue was Rs 266 crore (up 46% YoY).

Pranav Amin, managing director, Alembic Pharmaceuticals, said “The company grew in all the business segments with India outperforming the market with 9% growth, Ex US generics grew 46%, API grew 31% and the US generics business grew 6%. We have also started commercializing products from our Oncology and Injectable Facilities.”

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world.

Shares of Alembic Pharmaceuticals shed 0.11% to end at Rs 780.20 on Friday, 4 August 2023.